“…Using NGS in HNSCC, several different features have been disclosed between HPV + and HPV − cancers, including the potential of targeting some of them [ 28 , 43 , 49 , 67 , 105 , 106 , 107 , 108 , 109 ]. HPV + TSCC, BOTSCC, or OPSCC mainly presented mutations in the PIK3CA , notch homolog 1 translocation-associated (NOTCH1) , and FGFR3 genes, while HPV − tumors mainly had mutations in TP53 and cyclin-dependent kinase inhibitor 2A/B ( CDKN2A/B) [ 28 , 43 , 49 , 67 , 104 , 105 , 106 , 107 , 108 , 109 , 110 ]. The prognostic values of some of these genes have been reported, but there are discrepancies between the studies, and the data should be taken with caution.…”